Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The ...

Scientists at MedUni Vienna, led by Lukas Kenner, have made a groundbreaking discovery that could change how we understand ...

A new study has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought. A new study led by researchers at the UCLA Health ...

Brain metastases from prostate cancer (PC) seem to be more frequent than in the past, possibly because advances in the treatment of patients with castration-resistant PC have prolonged their survival.

The new urine test looks at 18 genes that are linked to high-risk prostate cancer. Previous research showed that MPS2 could ...

Patient was not fit for Docetaxel therapy and he was put on monthly Denosumab injection 120 mg/1 syringe, and Abiraterone ...

Prostate cancer is the second most common cancer affecting men globally, with diagnostic methods and risk assessment ...

The six biggest myths about prostate cancer – as it is named England’s most common cancer - There has been a 25 per cent ...

Prostate cancer is often seen as an unavoidable part of ageing, especially among men, but there are many myths that can create confusion.

The study, published in JAMA Network Open, found that nearly half of high-risk prostate cancer patients previously classified as nonmetastatic by conventional imaging actually have metastatic ...

Raymond Poole is a successful businessman. The 62-year -old has managed projects around the world. His Blessington office is ...

First patient treated in Phase II portion of clinical trial in metastatic prostate cancer at the West Los Angeles Veterans Administration ...